Syndax(SNDX) - 2022 Q4 - Earnings Call Transcript

First one just on the pool KMT2A cohort. Do you anticipate that the efficacy will be presented just for the pooled cohort on the label? Or could there also be a breakdown of AML and ALL on the label? Michael Metzger Yes, Joel, great question. I think that was sort of alluded to or part of another question that was asked earlier. The strategy for pooling is that the -- we'll be presenting a total number of patients and they'll be analyzed. I think the -- of course, the agency will look at all the subsets, an ...